Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Type 2 Diabetes | Unmet Need | US/EU | 2018

Login to access report north_east
Contact sales account_box

Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease. The 2018 Type 2 Diabetes Unmet Need content focuses on leading branded agents and analysis of more available clinical data. Several currently marketed agents have scope to further move up the treatment algorithm. Therefore, understanding physicians’ perception of these products has become increasingly important. This study reveals which drug attributes drive endocrinologists’ prescribing behavior and explores how current therapies compare across efficacy, safety, and delivery attributes.

Questions Answered

  • Which drugs offer the greatest ability to reduce HbA1c to target?
  • Which drug attributes are key influencers, which have limited impact, and which represent hidden opportunities?
  • What price range and clinical attributes of new T2D drugs are needed to influence physicians’ prescribing preference over current market players?
  • How do the leading diabetes brands compare among endocrinologists, and do opinions vary between U.S. and European physicians?

Product Description

Unmet Need provides quantitative insight into U.S. and European physicians’ perception of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, and the United Kingdom.

Primary research: Survey of 61 U.S. endocrinologists and 31 European endocrinologists.

Key drugs: Victoza, Trulicity, Invokana, Jardiance, Farxiga/Forxiga, Januvia, and Onglyza.

Key metrics included:

  • Stated versus derived analysis of U.S. and European physicians’ prescribing behavior.
  • Conjoint analysis with U.S. and European physicians includes market simulator.
  • Assessment of current therapies’ performance against treatment drivers and goals.
  • Physicians’ perception of unmet need in this disease and related indications.
  • Analysis of remaining drug development opportunities.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east